LENZ Therapeutics (LENZ) EBITDA (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of EBITDA data on file, last reported at -$42.2 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$42.2 million, down 187.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$109.6 million (down 130.11% YoY), and the FY2025 annual result was -$82.1 million, down 65.56% from the prior year.
• EBITDA retreated to -$42.2 million in Q1 2026 per LENZ's latest filing, from -$35.9 million in the prior quarter.
• Over five years, EBITDA peaked at -$9.6 million in Q3 2024 and troughed at -$42.2 million in Q1 2026.
• A 5-year average of -$20.6 million and a median of -$16.7 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2026: EBITDA soared 51.19% in 2023, then tumbled 187.1% in 2026.
• A 5-year view of EBITDA shows it stood at -$26.8 million in 2022, then grew by 11.48% to -$23.7 million in 2023, then soared by 45.19% to -$13.0 million in 2024, then plunged by 176.45% to -$35.9 million in 2025, then dropped by 17.56% to -$42.2 million in 2026.
• Business Quant data shows LENZ's EBITDA at -$42.2 million in Q1 2026, -$35.9 million in Q4 2025, and -$16.5 million in Q3 2025.